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Thromboxane Bz (TXB2) and 12-hydroxy-5,8,10,1Ceicosatetraenoic acid (12-HETE) formed from the 
endogenous and exogenous arachidonate during human platelet incubation, was evaluated by selected ion 
monitoring (SIM). TXBz formed from endogenous ubstrate accounted for about one third of the total, 
whereas the great part of 12-HETE derived from exogenous arachidonate. These data indicate that under 
the tested conditions the pool of arachidonate that acts as substrate for cycle-oxygenase is different from 
the pool that acts as substrate for lipoxygenase and that the arachidonate released from phospholipids is 
preferentially utilized by cycle-oxygenase. 
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1. INTRODUCTION 
The metabolic pathway of arachidonic acid in 
human platelets involves the oxygenation of the 
acid released from phospholipids, catalyzed by two 
enzymes, fatty acid cycle-oxygenase and lipox- 
ygenase. The cycle-oxygenase pathway generates 
thromboxane A2 (TXAz) and 12-hydroxy-5,8,10- 
heptadecatrienoic acid (HHT). The lipoxygenase 
pathway generates 12-hydroperoxy-5,8,10,14- 
eicosatetraenoic acid (12-HPETE) which is re- 
duced to the corresponding 1Zhydroxy acid (12- 
HETE) by a peroxidase [l]. 
While TXA2 has been shown to induce aggrega- 
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tion, the biological functions of the lipoxygenase 
metabolites in platelets are not fully understood. 
12-HPETE and 12-HETE appear to be 
chemotactic agents for human polymorphonuclear 
leukocytes [2,3]. It has also been suggested that the 
lipoxygenase products in human platelets may act 
as regulators of the arachidonate metabolism 
because 1ZHPETE was shown to stimulate in 
vitro its own production by increasing lipox- 
ygenase activity [4]. In addition, it has been 
reported [5] that the hydroperoxy acid inhibits the 
TXAZ synthesis. 
In view of the possible interference of 
arachidonate metabolites produced via the lipox- 
ygenase pathway on the cycle-oxygenase pathway, 
we investigated the competition of cycle-oxygenase 
and lipoxygenase for the common substrate, the 
arachidonate released from phospholipids. 
2. MATERIALS AND METHODS 
2.1. Materials 
[ 1-i4C]Arachidonic acid (54 mCi/mmol) 
was purchased from Amersham (International 
plc). N, 0-bis-(trimethylsilyl)-trifluoroacetamide 
(BSTFA) and pyridine were from Carlo Erba 
Published by Elsevier Science Publishers B. V. 
00145793/83/%3.00 0 1983 Federation of European Biochemical Societies 173 
Volume 157, number 1 FEBS LETTERS June 1983 
(Milan); Biosil-A 100-200 mesh from BioRad 
Laboratories (Richmond CA); thrombin from 
Topostasin, Roche. Other reagents and solvents 
were all of analytical grade. 
2.2. Platelet preparation 
Blood was collected in 0.15 volumes of an an- 
ticoagulant dextrose citrate from healthy donors 
who had not taken aspirin or any other antiinflam- 
matory drug during the week before collection. 
After centrifugation at 200 x g for 15 min platelet- 
rich plasma (PRP) was obtained and aliquots were 
subjected to platelet counting by contrast phase 
microscopy. Platelets recovered by centrifugation 
of the PRP at 800 x g for 15 min were suspended 
in 1 vol. Tris-saline buffer [6] in order to obtain 
a final concentraiton of lo9 platelets/ml. 
2.3. Platelet incubation 
Aliquots of the platelet suspension were prein- 
cubated for 2 min at 37°C and then incubated for 
5 min at the same temperature with various con- 
centrations of [I-i4C]arachidonic acid (1,5,10,100 
nmol/lO’ cells = l-100 ,uM) dissolved in ethanol. 
In some experiments thrombin (5 units/ml) and 
[l-‘4C]arachidonic acid (5 /IM) were added simul- 
taneously to aliquots of the preincubated platelet 
suspension and the mixture was incubated for 
5 min at 37°C. 
Incubations were stopped by the addition of 
20 vol. of CHCI3:CH3OH (2: 1; v/v). 12- 
[2Hg]HETE (156 pm&ml) and [2Hs]TXB2 
(280 pmol/ml) were also added to the samples 
before any other manipulation. Blank samples in- 
cubated in the absence of any added substrate were 
also analyzed. 
2.4. Analysis of the distribution of radioactivity 
in lipid extracts 
Total lipid extracts were counted for their 
radioactivity and then fractionated by column 
chromatography (0.5 g Biosil-A). Fraction A (hex- 
ane : diethyl ether; 85 : 15; v/v; 15 ml) contained 
arachidonate; 1ZHETE and HHT were recovered 
in fraction B (CHCl3; 15 ml); TXBz and PG, in 
fraction C (CHC13 :CH3OH; 95 : 5; v/v; 15 ml) and 
phospholipids in fraction D (CH30H; 9 ml, 
CH30H : H20; 99: 1; v/v; 6 ml). Fractions were 
counted for radioactivity and aliquots were sub- 
jected to thin-layer chromatography (TLC) 
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(CHC13 :CHsOH : CH3COOH : H20; 90: 8 : 1: 0.8; 
by vol.). The distribution of radioactivity on the 
plates was analyzed using a radiochromatoscanner 
(Packard model 7201). In order to check the identi- 
ty of the radioactive compounds aliquots of the 
fraction were also analyzed by radiogaschromato- 
graphy (RGLC) using a Carlo Erba gaschroma- 
tograph model GV connected with a Nuclear 
Chicago radioactivity counter model 4998 after 
esterification with an ethereal solution of dia- 
zomethane and silylation with a mixture of BSTFA 
and pyridine (4: 1; v/v). Analytical conditions 
were as described below. 
2.5. Evaluation of TXBz and I2-HETE formed 
from endogenous and exogenous 
arachidonate 
Aliquots of the esterified residue of fractions B 
and C were dissolved in BSTFA : pyridine (4: 1, 
v/v) and injected into a Varian Mat 112 S 
gaschromatograph-mass pectrometer. An 1 m x 
3 mm glass silanized column packed with 1% 
SE-30 on Gaschrom Q was used; oven, molecular 
separator and ion source were at 260, 300 and 
290°C respectively; electron energy 70 eV; elec- 
tron multiplier 3.5 kV; helium flow rate 
15 ml/min; resolution 300. For the analysis of 
TXBz the spectrometer was focused on ions at m/e 
256 and 258 for the detection of unlabelled and 
“C-labelled species and at m/e 260 for the 
deuterated internal standard [7]. For quantitation 
of TXB2 a linearity curve obtained from the 
analysis of standard samples containing deuterated 
and unlabelled TXBz was used. 
The curve showed a linear increase (Y = 0.83x f 
0.16; ? = 0.999) of the ratio of the intensities of 
the peaks in the traces of the ions at m/e 256 and 
260 (Y) with the increase of the ratio between the 
amount of unlabelled TXBz and the deuterated 
compound (x). A constant value (0.15) was instead 
observed for the ratio of the intensities of ions 
258/256 which derives from the natural isotopic 
abundance. Total amount of TXBz (nmol/109 
cells) in the samples was calculated from the sum 
of the intensities of the peaks at the retention time 
of the TXB2 derivative (5 min 20 s) in the trace of 
the ions at m/e 256, originating from endogenous 
substrate and in the trace of the ion at m/e 258 
originating from TXBz containing one atom of 14C 
per molecule: 
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TXBz (nmol/109 cells) = in the tissue could be hypothesized. 
l/a x [2Hs]TXB2 x 1256 + Z&Z256 
where: 
Z = intensity of the peak at the retention time of 
TXB2; 
a = slope of the standard curve; 
[2Hs]TXB2 = nmol/109 cells of deuterated stan- 
dard added after incubation. 
Moreover lipoxygenase, catalyzing the forma- 
tion of 1ZHETE is thought to be a cytoplasmic en- 
zyme [ 1 l] and could therefore be more accessible 
to the pool of free arachidonate than the mem- 
brane-bound cycle-oxygenase. In order to test this 
hypothesis we have studied the catabolism of 
exogenous and endogenous arachidonate in human 
platelets both to TXB2 and to 1ZHETE. 
14C-Enrichment was determined as the ratio of 
the intensity of ion at m/e 258 to the sum of inten- 
sities of ions at m/e 258 and 256. From this frac- 
tion the molar radioactivity (m.r.) of TXB2 iso- 
lated from the lipid extract after incubation was 
also calculated as follows: 
m.r. (dpm/nmol) = 64 nCi/nmol x 
2200 dpm/nCi x z258/z258, + 1256 
The intensity of the ion at 258 (Z258) was cor- 
rected for the contribution to the signal of the 
natural isotope determined in the analysis of the 
derivative of standard TXBt. In some experiments 
the addition of deuterated TXBz was avoided and 
molar radioactivity was evaluated from the mea- 
surement of the radioactivity associated with the 
compound after separation by TLC, as previously 
described, and the mass of the compound by radio- 
immunoassay (RIA). Levels and isotopic enrich- 
ment of 1ZHETE formed during platelet incuba- 
tion were determined in fraction B as described for 
TXBz from the intensities of the peaks in the traces 
of the ions at 295, 297 and 301 [7] corresponding 
to unlabelled, labelled and deuterated species, at 
the retention time of the 12-HETE derivative 
(3 min 40 s). 
For this purpose using [l-14C]arachidonate with 
high molar radioactivity as the exogenous 
substrate the 14C-enrichment in TXBz and 
12-HETE formed during platelet incubation was 
evaluated by the SIM. This approach allows to dif- 
ferentiate the contribution of the endogenous and 
exogenous substrates in the formation of the 
metabolites. Because 64 mCi/mmol corresponds 
to the molar radioactivity of a compound contain- 
ing one atom of 14C per molecule with 100% 
isotopic abundance, commercial [l-‘4C]arachi- 
donic acid with 50-55 mCi/mmol molar radio- 
activity has an isotopic enrichment of 78-85%. 
3. RESULTS AND DISCUSSION 
The isotopic abundance of [l-‘4C]arachidonic 
acid used in the described experiments was deter- 
mined by SIM analysis of its methyl ester from the 
ratio of the intensities of the peaks on the traces of 
ions at m/e 322 and 320, corresponding to the M+ 
of 1-i4C-labelled and unlabelled species, respec- 
tively. Ratio was found to be 5.4, in good agree- 
ment with the theoretical value of 5.2 calculated on 
the basis of the 54 mCi/mmol molar radioactivity 
of the compound. In unlabelled arachidonic 
methyl ester the ratio was found to be 0.07. The 
latter value should be found for TXB2 and 
IZHETE originating from the endogenous precur- 
sor whereas an increase of the isotopic enrichment 
should be observed if exogenous arachidonate par- 
ticipates to the formation of these metabolites too. 
Most of the arachidonate is present in tissues as 
an acyl-group in phospholipids and the compound 
is released in the free form and acts as the substrate 
for cycle-oxygenase [8] when synthesis of pro- 
stanoids is required. In view of the finding that ex- 
ogenous arachidonate added to tissue homogenate 
or cultured cells [9,10] is converted to prostanoids 
less efficiently than the endogenous substrate, a 
direct transfer of the acyl-group of phospholipids 
to the enzyme catalyzing its transformation 
without previous mixing with the free form present 
The amount and the degree of isotopic enrich- 
ment of TXB2 formed in incubations of human 
platelets with various concentrations of [1-‘4C]- 
arachidonate is reported in table 1. Cyclo-oxy- 
genase activity measured as TXB2 formation in- 
creased with the concentration of the labelled 
substrate and seemed to reach the saturation 
gradually [ 121. 
The ratio between labelled and unlabelled 
species of TXB2 decreased from 5 FM to 10 pM 
arachidonate and then remained almost constant. 
Molar radioactivity determined by TLC and RIA 
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Table 1 
TXB2 formed from [12C] and [‘%‘]arachidonate in incubations of human platelets 
June 1983 
Substrate TXBza Ratio of intensitiesb Molar radioactivity 
[ 1 -14C]AA (54 nCi/nmol) nmol/lOp cells m/e 258 (from [14C]AA) dpm/nmol W3 
FM by RIA m/e 256 (from [r2C]AA) by RIA by SIM 
1 0.05 - 
5 0.43 4.6 115 120 
10 1.30 1.3 80 80 
50 3.53 1.7 77 89 
100 4.60 1.8 81 90 
5 + Thrombin 
(5 units/ml) 8.50 5 
a Values are subtracted from the mean TXB2 concentration (0.01) nmol/lOg cells obtained in blank samples in which 
platelets were incubated in the absence of added arachidonate 
b Mean ratios in blank samples (0.15) were subtracted 
Values are means of 3 experiments with different platelet preparations. Each assay was made in triplicate 
showed the same trend. These data indicate an in- 
creasing grade of dilution of the added substrate 
with endogenous non-labelled arachidonate releas- 
ed from phospholipids. It appears, therefore, that 
exogenous arachidonate induces the release of the 
acid esterified in phospholipids in a concentration- 
dependent manner. 
When 5 pM labelled arachidonate was incubated 
in the presence of thrombin, the obtained TXB2 
did not contain detectable amounts of labelled 
species as expected from the massive release of 
arachidonate induced by thrombin. Nevertheless, 
the mount of TXBz was only twice that obtained 
in incubations carried out with 100 FM exogenous 
arachidonate, which is in agreement with previous 
data showing the saturation of cycle-oxygenase at 
100 pM substrate concentration 1121. 
A different picture was obtained for 12-HETE 
(table 2). Its formation increased linearly (r” = 
0,998) with the labelled substrate concentration as 
expected from results indicating that saturation of 
lipoxygenase occurs at a higher concentration of 
arachidonate [12]. The isotopic enrichment of 
1%HETE also increased with the substrate concen- 
tration being almost IO-times that of TXB2 at 
arachidonate concentrations higher than 10 FM. 
This suggests that arachidonate released from 
phospholipids is poorly utilizied for the production 
of 12-HETE by lipoxygenase. The experiments in 
the presence of thrombin confirm this conclusion: 
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the amount of 12-HETE formed was only 30% 
higher than that observed at 1OpM exogenous 
arachidonate despite the release of large amounts 
of substrate from phospholipids described above. 
An unexpected result in the analysis of the 
isotopic enrichment of 1ZHETE was the absolute 
Table 2 
12-HETE formed from [“Cl and [*4C]arachidonate in
incubations of human platelets 
Substrate 12-HETE 
f l-14C]AA nmol/ 10’ 
(54 nCi/nmol) cells 
OtM) by SIM 
Ratio of intensitiesa 
m/e 297 
(from [‘4C]AA) 
m/e 295 
{from [“C]AA) 
1 0.09 1.7 
5 0.74 4.9 
10 1.90 10.8 
40 7.10 12.0 
100 13.40 15.0 
5 + thrombin 
(5 units/ml) 2.90 0.2 
a Mean ratios (0.1) in blank samples obtained in 
incubations of human platelets without added 
arachidonate were subtracted 
Values are means of 3 experiments with different platelet 
preparations. Each assay was made in triplicate 
Volume 157, number 1 FEBSLETTERS June 1983 
Fig.1. 12-HETE formed from [“Cl- and [14C]arachi- 
donate in incubations of human platelets. 
value of the ratio of intensities of ions at m/e 297 
and 295, which exceeded that of the added 
substrate. Since arachidonate is likely to be involv- 
ed in metabolic pathways other than those catalyz- 
ed by cycle-oxygenase and lipoxygenase, the 
isotopic enrichment of the substrate giving rise to 
IZHETE may depend upon an isotopic effect in 
any unidentified fast reaction utilizing free 
arachidonate. 
Fig.1 and 2 show the contribution of labelled 
and unlabelled substrate in the formation of the 
total amount of TXBz and 1ZHETE after incuba- 
tion of human platelets, with the result that the 
TXB2 formed from the endogenous substrate ac- 
counts for about l/3 of the total, whereas 
5- 
“0 
7 
f 2.5- 
I d 
I I 
50 loo 
k- “C] AA nmcks / 109 cells 
Fig.2. TXBZ formed from [“Cl- and [14C]arachidonate 
in incubations of human platelets. 
1ZHETE derives almost quantitatively from ex- 
ogenous arachidonate. 
In conclusion these experiments indicate that 
under the tested conditions the pool of 
arachidonate that acts as a substrate for the cyclo- 
oxygenase differs from that accessible to the lipox- 
ygenase. This corresponds well with data presented 
in [13] showing that platelet lipoxygenase can 
utilize arachidonic acid derived from plasma 
phospholipids whereas platelet cycle-oxygenase 
preferentially utilizes that derived from platelet 
phospholipids. 
These findings may suggest hat the enzyme and 
phospholipids from which the substrate is released 
are confined to the same or to closely related 
membranes. 
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